DelveInsight’s “Dementia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Dementia, historical and forecasted epidemiology as well as the Dementia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Dementia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dementia Market Forecast
Some of the key facts of the Dementia Market Report:
-
The Dementia market size was valued approximately USD 21 million in 2021 and is anticipated to grow with a significant CAGR of 2.42% during the study period (2019-2032)
-
In 2022, the estimated total prevalence of dementia cases across the 7MM was 22,112,602, with a projected Compound Annual Growth Rate (CAGR) expected to be notably higher during the study period.
-
In 2022, there were 11,751,680 diagnosed cases of dementia identified in the 7MM, with expectations of further increases during the study period spanning from 2019 to 2032.
-
As per the Centers for Disease Control and Prevention (2022), Alzheimer’s disease stands as the predominant form of dementia. Current statistics suggest approximately 5.8 million individuals in the United States are affected by Alzheimer’s disease and related dementias, comprising 5.6 million individuals aged 65 and above, and roughly 200,000 individuals under 65 with early-onset Alzheimer’s.
-
According to Dementia UK (2023), the estimated number of people living with dementia in the UK surpasses 900,000 individuals.
-
Key Dementia Companies: EIP Pharma Inc, Sun Pharma Advanced Research Company Limited, Pfizer, Allyx Therapeutics, BioXcel Therapeutics Inc, Prevail Therapeutics, Eli Lilly and Company, Cerevel Therapeutics, LLC, Cognition Therapeutics, Alector Inc., Athira Pharma, Otsuka Pharmaceutical Development & Commercialization, Inc., Karuna Therapeutics, CuraSen Therapeutics, Inc., Passage Bio, Inc., Suven Life Sciences Limited, Biogen, Sage Therapeutics, Transposon Therapeutics, Inc., Axsome Therapeutics, Inc., Janssen Research & Development, LLC, TrueBinding, Inc., Merck Sharp & Dohme LLC, Cassava Sciences, Inc., BioVie Inc., Vivoryon Therapeutics N.V., Alnylam Pharmaceuticals, and others
-
Key Dementia Therapies: Neflamapimod, K0706, Bosutinib, BMS-984923, BXCL501, PR006, CVL-871, CT1812, AL001, ATH-1017, AVP-786, KarXT, CST-2032, PBFT02, Masupirdine, BIIB080, SAGE-718, TPN-101, AXS-05, JNJ-63733657, Donanemab, TB006, MK-2214, Simufilam, NE3107, Aducanumab, PQ912, SAGE-718, ALN-APP, and others
-
The Dementia epidemiology based on age-specific cases analyzed that Dementia (VaD) is highly prevalent in age group of 60 years and above, while below this age group the disease appears to be rare
-
The Dementia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dementia pipeline products will significantly revolutionize the Dementia market dynamics.
Dementia Overview
An etiological category of dementia known as Dementia (VaD) is defined by significant cognitive impairment brought on by an ischemia or hemorrhagic stroke or by hypoperfusion of brain areas crucial for memory, cognition, and behavior.
Get a Free sample for the Dementia Market Report:
https://www.delveinsight.com/report-store/dementia-market
Dementia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Dementia Epidemiology Segmentation:
The Dementia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
-
Total Prevalence of Dementia
-
Prevalent Cases of Dementia by severity
-
Gender-specific Prevalence of Dementia
-
Diagnosed Cases of Episodic and Chronic Dementia
Download the report to understand which factors are driving Dementia epidemiology trends @ Dementia Epidemiology Forecast
Dementia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dementia market or expected to get launched during the study period. The analysis covers Dementia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Dementia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Dementia Therapies and Key Companies
-
Neflamapimod: EIP Pharma Inc
-
K0706: Sun Pharma Advanced Research Company Limited
-
Bosutinib: Pfizer
-
BMS-984923: Allyx Therapeutics
-
BXCL501: BioXcel Therapeutics Inc
-
PR006: Prevail Therapeutics/Eli Lilly and Company
-
CVL-871: Cerevel Therapeutics, LLC
-
CT1812: Cognition Therapeutics
-
AL001: Alector Inc.
-
ATH-1017: Athira Pharma
-
AVP-786: Otsuka Pharmaceutical Development & Commercialization, Inc.
-
KarXT: Karuna Therapeutics
-
CST-2032: CuraSen Therapeutics, Inc.
-
PBFT02: Passage Bio, Inc.
-
Masupirdine: Suven Life Sciences Limited
-
BIIB080: Biogen
-
SAGE-718: Sage Therapeutics
-
TPN-101: Transposon Therapeutics, Inc.
-
AXS-05: Axsome Therapeutics, Inc.
-
JNJ-63733657: Janssen Research & Development, LLC
-
Donanemab: Eli Lilly and Company
-
TB006: TrueBinding, Inc.
-
MK-2214: Merck Sharp & Dohme LLC
-
Simufilam: Cassava Sciences, Inc.
-
NE3107: BioVie Inc.
-
Aducanumab: Biogen
-
PQ912: Vivoryon Therapeutics N.V.
-
SAGE-718: Sage Therapeutics
-
ALN-APP: Alnylam Pharmaceuticals
Discover more about therapies set to grab major Dementia market share @ Dementia Treatment Market
Dementia Market Strengths
-
The increasing prevalent population in the 7MM is likely to cause an upsurge in treatment need. Consequently, with successful launch of emerging therapies, the market will witness a boost in the upcoming year.
Dementia Market opportunities
-
Medications with better safety and effectiveness, which provide optimum care are the current unmet need of the VaD disease market.
Scope of the Dementia Market Report
-
Study Period: 2019–2032
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Dementia Companies: EIP Pharma Inc, Sun Pharma Advanced Research Company Limited, Pfizer, Allyx Therapeutics, BioXcel Therapeutics Inc, Prevail Therapeutics, Eli Lilly and Company, Cerevel Therapeutics, LLC, Cognition Therapeutics, Alector Inc., Athira Pharma, Otsuka Pharmaceutical Development & Commercialization, Inc., Karuna Therapeutics, CuraSen Therapeutics, Inc., Passage Bio, Inc., Suven Life Sciences Limited, Biogen, Sage Therapeutics, Transposon Therapeutics, Inc., Axsome Therapeutics, Inc., Janssen Research & Development, LLC, TrueBinding, Inc., Merck Sharp & Dohme LLC, Cassava Sciences, Inc., BioVie Inc., Vivoryon Therapeutics N.V., Alnylam Pharmaceuticals, and others
-
Key Dementia Therapies: Neflamapimod, K0706, Bosutinib, BMS-984923, BXCL501, PR006, CVL-871, CT1812, AL001, ATH-1017, AVP-786, KarXT, CST-2032, PBFT02, Masupirdine, BIIB080, SAGE-718, TPN-101, AXS-05, JNJ-63733657, Donanemab, TB006, MK-2214, Simufilam, NE3107, Aducanumab, PQ912, SAGE-718, ALN-APP, and others
-
Dementia Therapeutic Assessment: Dementia current marketed and Dementia emerging therapies
-
Dementia Market Dynamics: Dementia market drivers and Dementia market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Dementia Unmet Needs, KOL’s views, Analyst’s views, Dementia Market Access and Reimbursement
To know more about Dementia companies working in the treatment market, visit @ Dementia Clinical Trials and Therapeutic Assessment
Table of Contents
1. Dementia Market Report Introduction
2. Executive Summary for Dementia
3. SWOT analysis of Dementia
4. Dementia Patient Share (%) Overview at a Glance
5. Dementia Market Overview at a Glance
6. Dementia Disease Background and Overview
7. Dementia Epidemiology and Patient Population
8. Country-Specific Patient Population of Dementia
9. Dementia Current Treatment and Medical Practices
10. Dementia Unmet Needs
11. Dementia Emerging Therapies
12. Dementia Market Outlook
13. Country-Wise Dementia Market Analysis (2019–2032)
14. Dementia Market Access and Reimbursement of Therapies
15. Dementia Market Drivers
16. Dementia Market Barriers
17. Dementia Appendix
18. Dementia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/